WOUND SCREEN

• US 20150018524A1
• Filed: 02/12/2013
• Published: 01/15/2015
• Est. Priority Date: 02/15/2012
• Status: Abandoned Application

• Current Assignee: Microarray Limited
• Original Assignee: Archimed LLP (3M Company)
• Inventors: Davis, Paul James
• Application Number:
  US14/374,079
• Publication Number:
  US 20150018524A1
• Time in Patent Office: Days
• US Class Current: 530/377
• CPC Class Codes: A61L 15/28 Polysaccharides or their derivatives A61L15/225 takes precedence
• CPC Class Codes: A61L 15/32 Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin A61L15/225 takes precedence
• CPC Class Codes: A61L 15/425 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 15/46 Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 2300/204 with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: C08L 1/02 Cellulose; Modified cellulose
• CPC Class Codes: C08L 1/04 Oxycellulose; Hydrocellulose , e.g. microcrystalline cellulose

Abstract

A binding screen comprising a gas-porous solid non-water-dispersible carrier, to which has been substantially irreversibly bound a compound having matrix metalloproteinase binding functionality, particularly doxycycline.

Claims

1. A matrix metalloproteinase binding screen, comprising a gas-porous solid non-water-dispersible carrier, to which has been substantially irreversibly bound a compound having and retaining matrix metalloproteinase binding functionality.

2. A method of preparing the screen according to claim 1, wherein a compound having matrix metalloproteinase binding functionality is converted into a chemically active derivative having a chemically active site and leaving the matrix metalloproteinase binding functionality substantially unaffected, which compound is then brought into contact with the carrier and is substantially irreversibly bound thereto via the chemically active site.

3. The method according to claim 2, wherein the compound having matrix metalloproteinase binding functionality is converted into a chemically active derivative by introducing an amine group.

4. The method according to claim 3, wherein the carrier comprises cotton having β

-D-glucopyranose residues, which is treated with sodium periodate, which oxidises the β

-D-glucopyranose residues to give free aldehydes, the amine derivative then being mixed with the treated cotton to form a mix, so that the aldehydes undergo nucleophilic attack by the free amine to form carbinolamines, the mix then subsequently being treated with a reducing agent which both reduces any unreacted free aldehydes, thus preventing any unwanted further reactions, and also reduces carbinolamines to alkylamines.

5. The method according to claim 3, wherein the amine functionality is further converted by biotinylation to add a biotin, and then brought into contact with the carrier, which has been modified with an avidin derivative or analogue, to allow the biotin and avidin to bind together.

6. The screen according to claim 1, wherein the compound having matrix metalloproteinase binding functionality comprises a tetracycline antibiotic.

7. The screen according to claim 6, wherein the tetracycline antibiotic is doxycycline.

8. The screen according to claim 1, wherein the screen is non-swellable.

9. The screen according to claim 1, wherein the carrier comprises cotton and alkylamines.

10. The method according to claim 2, wherein the compound having matrix metalloproteinase binding functionality comprises a tetracycline antibiotic.

11. The method according to claim 10, wherein the tetracycline antibiotic is doxycycline.

12. The method according to claim 2, wherein the screen is non-swellable.